Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Human tumours typically harbour a remarkable number of somatic mutations. If presented on major histocompatibility complex class I molecules (MHCI), peptides containing these mutations could potentially be immunogenic as they should be recognized as 'non-self' neo-antigens by the adaptive immune system. Recent work has confirmed that mutant peptides can serve as T-cell epitopes. However, few mutant epitopes have been described because their discovery required the laborious screening of patient tumour-infiltrating lymphocytes for their ability to recognize antigen libraries constructed following tumour exome sequencing. We sought to simplify the discovery of immunogenic mutant peptides by characterizing their general properties. We developed an approach that combines whole-exome and transcriptome sequencing analysis with mass spectrometry to identify neo-epitopes in two widely used murine tumour models. Of the >1,300 amino acid changes identified, ∼13% were predicted to bind MHCI, a small fraction of which were confirmed by mass spectrometry. The peptides were then structurally modelled bound to MHCI. Mutations that were solvent-exposed and therefore accessible to T-cell antigen receptors were predicted to be immunogenic. Vaccination of mice confirmed the approach, with each predicted immunogenic peptide yielding therapeutically active T-cell responses. The predictions also enabled the generation of peptide-MHCI dextramers that could be used to monitor the kinetics and distribution of the anti-tumour T-cell response before and after vaccination. These findings indicate that a suitable prediction algorithm may provide an approach for the pharmacodynamic monitoring of T-cell responses as well as for the development of personalized vaccines in cancer patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that only a small fraction of presented tumor mutations are immunogenic in cancer patients (45, 46), our findings suggest that relatively small differences in the number of available HLA-I molecules in a given individual can present major challenges to effective antitumor T cell responses and efficacy to ICB.”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [46]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
GMAP: A genomic mapping and alignment program for mRNA and EST sequences
Wu, T. D., & Watanabe, C. K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti310 · Cited by 2,354
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., & Cunningham, F. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq330 · Cited by 1,586
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
HOW TCRS BIND MHCS, PEPTIDES, AND CORECEPTORS
Rudolph, M. G., Stanfield, R. L., & Wilson, I. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115658 · Cited by 1,310
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. M., Oseroff, C., Yuan, L., Ruppert, J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.12.5586 · Cited by 830
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., & Nielsen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn202 · Cited by 808
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Brown, S. D., Warren, R. L., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 594
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Rosetta FlexPepDock web server—high resolution modeling of peptide–protein interactions
London, N., Raveh, B., Cohen, E., Fathi, G., & Schueler-Furman, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr431 · Cited by 402
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
Goldberg, A. L. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350012 · Cited by 367
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Young, A. C. M., Zhang, W., Sacchettini, J. C., & Nathenson, S. G. (1994) · Cell · doi:10.1016/0092-8674(94)90171-6 · Cited by 247
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma
Bertsch, E., Qiang, W., Zhang, Q., Espona-Fiedler, M., Druschitz, S., Liu, Y., Mittal, K., Kong, B., Kurita, T., & Wei, J.-J. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.243 · Cited by 172
The MHC class I peptide repertoire is molded by the transcriptome
Fortier, M.-H., Caron, E., Hardy, M.-P., Voisin, G., Lemieux, S., Perreault, C., & Thibault, P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071985 · Cited by 171
Wick, D. A., Webb, J. R., Nielsen, J. S., Martin, S. D., Kroeger, D. R., Milne, K., Castellarin, M., Twumasi-Boateng, K., Watson, P. H., Holt, R. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2147 · Cited by 152
Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
Gujar, S. A., Pan, D., Marcato, P., Garant, K. A., & Lee, P. W. K. (2011) · Molecular Therapy · doi:10.1038/mt.2010.297 · Cited by 95
Structural Evidence of T Cell Xeno-reactivity in the Absence of Molecular Mimicry
Zhao, R., Loftus, D. J., Appella, E., & Collins, E. J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.359 · Cited by 82
MHC I–associated peptides preferentially derive from transcripts bearing miRNA response elements
Granados, D. P., Yahyaoui, W., Laumont, C. M., Daouda, T., Muratore‐Schroeder, T. L., Côté, C., Laverdure, J., Lemieux, S., Thibault, P., & Perreault, C. (2012) · Blood · doi:10.1182/blood-2012-02-412593 · Cited by 77
Affinity Thresholds for Naive CD8+ CTL Activation by Peptides and Engineered Influenza A Viruses
Denton, A. E., Wesselingh, R., Gras, S., Guillonneau, C., Olson, M. R., Mintern, J. D., Zeng, W., Jackson, D. C., Rossjohn, J., Hodgkin, P. D., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003937 · Cited by 63
Ostrov, D. A., Roden, M. M., Shi, W., Palmieri, E., Christianson, G. J., Mendoza, L. M., Villaflor, G., Tilley, D., Shastri, N., Grey, H. M., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.283 · Cited by 38
Peptidic Termini Play a Significant Role in TCR Recognition
Wang, B., Sharma, A. K., Maile, R., Saad, M., Collins, E. J., & Frelinger, J. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.3137 · Cited by 21
Structural and Biological Basis of CTL Escape in Coronavirus-Infected Mice
Butler, N. S., Theodossis, A., Webb, A. I., Dunstone, M. A., Nastovska, R., Ramarathinam, S. H., Rossjohn, J., Purcell, A. W., & Perlman, S. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3926 · Cited by 19
Cited by
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
“They support the view that the number and type of alterations may prove to be valuable for judging the potential usefulness of immune checkpoint inhibitors, even in mismatch repair–proficient cancers.(41,48,54) Most importantly, our results show an approach for the treatment of a specific class of tumors that is based…”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Metadata
- Authors
- Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., Modrusan, Z., Mellman, I., Lill, J. R., & Delamarre, L.
- Affiliations
- Genentech (US)
- Immatics Biotechnologies (Germany) (DE)
- Corresponding author
- Lill, Jennie R.
- Delamarre, Lélia
- ORCID
- Venue
- Nature
- Published
- 2014-11-26
- Volume
- 515
- Issue
- 7528
- Pages
- 572-576
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2006759360
- Cited by
- 1,186
- References
- 38
- Citations by year
- 2026: 62 · 2025: 88 · 2024: 74 · 2023: 72 · 2022: 98 · 2021: 135 · 2020: 126 · 2019: 116 · 2018: 101 · 2017: 114 · 2016: 104 · 2015: 89 · 2014: 5
- FWCI
- 42.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- T cell epitopes, MHC class I binding, MHC binding prediction, solvent accessibility, cytotoxic T lymphocyte response, pharmacodynamic monitoring, personalized cancer vaccines
- MeSH terms
- Animals, Female, Immunity, Cellular, Mice, Inbred C57BL, Models, Molecular, Mutation, Neoplasms, Peptides, Mass Spectrometry, Protein Structure, Tertiary, CD8-Positive T-Lymphocytes, Cancer Vaccines, Gene Expression Profiling, Cell Line, Tumor, Immunoprecipitation, Mice, Immunogenetic Phenomena, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.